BIIB financials
Biogen Inc. · end-of-day data as of Oct 16, 2026
Biogen Inc.
$232.65+15.1%
Buy · 37 analystsPT $238.98 +2.7%
BIIB reported revenue of $2.74B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 3.4% from a year earlier. It posted diluted EPS of $0.66, free cash flow of $490M and a net margin of 3.6%.
Valuation
- P/E41.2x
- P/E vs own+81.9%
- P/E vs sector+46.3%
- FCF yield+8.6%
- Market cap$34.37B
Quarterly results
Q2 FY2026: Revenue +3.4% year over year, free cash flow 17.9% of revenue, operating margin 11.6%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $2.74B | 0.66 | $490M | 56.9% | 11.6% | 3.6% |
| Q1 FY2026 | Mar 31, 2026 | $2.48B | 2.15 | $697M | 73.3% | 16.0% | 12.9% |
| Q4 FY2025 | Dec 31, 2025 | $2.28B | -0.33 | $556M | 78.2% | -2.5% | -2.1% |
| Q3 FY2025 | Sep 30, 2025 | $2.45B | 3.17 | $1.23B | 64.3% | 25.0% | 19.0% |
| Q2 FY2025 | Jun 30, 2025 | $2.65B | 4.35 | $144M | 64.2% | 22.2% | 24.0% |
| Q1 FY2025 | Mar 31, 2025 | $2.43B | 1.64 | $212M | 76.2% | 30.1% | 9.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.45B | 1.83 | $695M | 76.2% | 20.7% | 10.9% |
| Q3 FY2024 | Sep 30, 2024 | $2.47B | 2.66 | $806M | 74.1% | 23.4% | 15.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.46B | 4.00 | $583M | 61.2% | 14.9% | 23.7% |
| Q1 FY2024 | Mar 31, 2024 | $2.29B | 2.70 | $432M | 78.3% | 30.1% | 17.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.39B | 1.71 | -$52.7M | 74.1% | 21.5% | 10.5% |
| Q3 FY2023 | Sep 30, 2023 | $2.53B | -0.47 | $505M | 73.9% | 12.7% | -2.7% |